Mounjaro®
Starting from £179.99/mo
Start journey Learn moreNausea is the most commonly reported side effect of Wegovy (semaglutide), and for many people it peaks in the first few weeks of treatment or after a dose increase. It is real, it can be disruptive, and it does not mean the medicine is harming you. Most people find it settles as the body adjusts, though for some it persists or is severe enough to need clinical support. Wegovy is a prescription-only medicine; a qualified prescriber assesses suitability and guides any changes to your treatment.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
This is the misconception our prescribers hear most often. Patients assume nausea is a warning sign — that their body is rejecting the medicine, or that something has been dispensed incorrectly. In fact, the opposite is closer to the truth. Wegovy works partly by slowing the rate at which food leaves the stomach, a mechanism that increases fullness but also causes that unsettled, queasy feeling, particularly when the medicine is new to the body or a dose has just increased.
The NHS medicines page for semaglutide lists nausea, vomiting, diarrhoea, constipation, indigestion, and burping as common side effects, common meaning they affect more than one in ten people. That is not a small minority. If you have found yourself feeling sick from semaglutide, you are in the company of a large proportion of people who start this treatment.
What should shift your thinking is duration and intensity. Mild-to-moderate nausea that comes and goes, especially around mealtimes or in the evening, fits the expected pattern. Nausea so severe you cannot keep fluids down, or that shows no improvement after two or three weeks at a stable dose, is worth discussing with your prescriber. The distinction matters because the response is different: one calls for reassurance and practical tips, the other may call for a clinical review of your dose or timing.
Several habits amplify Wegovy-related nausea without people realising it. Eating quickly, having large portions, lying down soon after a meal, and eating fatty or rich food all compound the effect of slowed gastric emptying. So does drinking a large glass of water mid-meal rather than sipping steadily through the day.
The adjustments that tend to help are genuinely simple. Smaller meals eaten more slowly, with a gap of at least two hours before lying down. Bland, lower-fat foods during the adjustment period. Cold or room-temperature drinks rather than hot ones if nausea is acute. Ginger in any form (tea, biscuits, lozenges) has reasonable evidence behind it for general nausea relief, though it does not interact with the medicine in a therapeutic way.
One practical note: a lot of people find that the nausea is at its most manageable in the morning when they have had a light breakfast, and it builds if they skip meals entirely. Skipping food to avoid nausea tends to backfire on Wegovy, an empty stomach can actually make the sensation worse. There is no single correct eating pattern, but most people settle into something that works for them within a few weeks. If you want structured guidance, a prescriber or dietitian can help you find it without guesswork. You can also read more about what the broader side-effect picture looks like on our Wegovy side effects overview.
Most nausea from Wegovy does not require urgent action. Some does. The MHRA issued a Drug Safety Update in January 2026 specifically highlighting acute pancreatitis as a known but infrequent serious risk with GLP-1 medicines, including semaglutide. The symptom to act on is severe, persistent stomach pain (often felt in the upper abdomen and radiating into the back) that does not pass quickly and may come with vomiting. Our page on being sick on Wegovy goes into more detail on how to tell this apart from ordinary treatment nausea, and anyone experiencing it should seek same-day medical assessment rather than waiting to see if it settles. You can report suspected side effects directly through the MHRA Yellow Card scheme.
Other situations that warrant a call to your prescriber or GP include: vomiting so frequent you cannot keep fluids down for more than 24 hours (dehydration is a genuine risk); signs of a severe allergic reaction such as facial swelling, difficulty breathing, or a spreading rash; and persistent, unexplained changes in bowel habit after the initial settling-in period. Low mood or changes in mental health, though not a widely publicised side effect, should also be mentioned to a clinician.
Fatigue and headache are also listed common side effects, they tend to be mild and transient. Dizziness is reported by some people, often linked to eating less and reduced caloric intake rather than a direct drug effect. If you are unsure whether what you are experiencing falls within the expected range, our guidance on identifying a side effect from Wegovy can help you decide whether to seek clinical input. Getting clinical oversight matters more on a prescription medicine than for most over-the-counter products.
Stopping Wegovy abruptly because of nausea is one of the more common reasons people do not complete treatment, and it is often avoidable. The licensed titration schedule exists precisely to reduce the severity of GI side effects: the body is given time at each dose level to adapt before moving higher. If nausea is severe, staying at the current dose for longer than the standard interval is often a more appropriate response than stopping altogether. That decision belongs with your prescriber.
It is also worth knowing that returning to Wegovy after a gap can bring the side effects back, as though restarting from scratch. So a short pause does not always give the relief people hope for. If you are weighing up whether the side effects justify continuing, that conversation is exactly what our clinical team is there for, to give you an honest picture of your options, not just reassurance. Some people genuinely find that Wegovy is not the right fit and that another approach suits them better. Others find that a small adjustment to dose timing resolves the issue entirely.
If you are exploring whether semaglutide treatment is right for you given the side-effect profile, it is worth understanding the full cost of Wegovy treatment alongside the clinical picture before making a decision. And if you have had no side effects at all and are wondering whether the medicine is working, there is a separate discussion to have, one that looks at how weight response and side-effect experience relate to each other. Our page on experiencing no side effects from Wegovy covers that specifically.
When you are ready to speak with a prescriber about starting or reviewing treatment, you can check your eligibility through a free consultation, reviewed the same day by a real clinician, not an automated queue.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.